GlassScriptPhysician profile
Steven Dylan Hubbard
NPI 1861909426
$9,259.91
in general payments reported to CMS, 2019-2025
22 companies · $3,434 in 2025
The $3,434 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $205 · 2023: $2,605 · 2024: $3,015 · 2025: $3,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,849 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,849.24 |
| Education | $205.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,451.02 | 2022-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,352.53 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $809.14 | 2022-2025 | Ofev, Spiriva Respimat, Jascayd |
| Regeneron Healthcare Solutions, INC. | $750.90 | 2023-2025 | Dupixent |
| Genzyme Corporation | $699.91 | 2023-2025 | |
| Baxter Healthcare | $699.43 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $640.06 | 2022-2025 | Glassia |
| Grifols USA, LLC | $424.55 | 2023-2025 | Prolastin-C Liquid |
| Insmed, INC. | $361.90 | 2023-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $355.15 | 2023-2024 | Yupelri |
| United Therapeutics Corporation | $251.30 | 2023-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $224.97 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Amgen INC. | $205.01 | 2023-2025 | Tezspire |
| Electromed, INC. | $183.72 | 2024-2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $174.79 | 2023-2025 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $167.69 | 2023-2025 | Inogen At Home Stationary Concentrator |
| Ani Pharmaceuticals, INC. | $135.34 | 2023-2024 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $126.98 | 2023-2025 | |
| Verona Pharma, INC. | $107.55 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $80.86 | 2025 | Yupelri |
| Philips North America LLC | $34.49 | 2025 | Vest Therapy Und |
| Daiichi Sankyo INC. | $22.62 | 2023 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hubbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.